GAINESVILLE, Fla., April 15, 2010 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCBB:QMDT) announced today that it will profile an innovative new wound dressing that incorporates its unique and proprietary NIMBUS® technology at the 2010 Symposium on Advances in Wound Care/Wound Healing Society meeting. This event is the premier meeting of physicians, researchers and other wound care specialists and is being held in Orlando, Florida, on April 17-20, 2010.
This novel dressing is being developed by Quick-Med Technologies for the treatment of vesicant injuries. The dressing is specifically designed to promote optimal wound healing by providing not only a moist wound healing environment with non-leaching antimicrobial protection but also protease inhibiting properties through sustained delivery of an antibiotic that also acts as a protease inhibitor, as well as antioxidants and a growth factor.
The work is being undertaken by Quick-Med under a Small Business Innovation Research (SBIR) grant from the U.S. Army Medical Research and Material Command. The Small Business Innovation Research program allows small, high-tech U.S. businesses and academia the opportunity to provide innovative research and development solutions in response to critical Army needs.
During the Symposium, Quick-Med scientists will present exciting findings that demonstrate a measurable improvement to the wound healing process using a NIMBUS superabsorbent dressing containing controlled releasable adjuncts with an in-vivo pig model. According to Dr. Jerry Olderman, Quick-Med's Vice President of Research & Development, "this excellent research study sets the stage for the development of advanced wound dressings that employ NIMBUS technology for the enhancement and acceleration of wound healing."
The goal of the SBIR research project was to develop a wound dressing prototype capable of enhancing the healing of debrided vesicant wounds and other injuries. This objective has been achieved using an advanced antimicrobial NIMBUS superabsorbent dressing modified by the addition of a slowly released composition comprising a protease inhibitor, an epidermal growth factor and antioxidant vitamins C and E. Significant improvement in the wound healing outcome compared to an untreated control dressing was observed based on collagen deposition, epidermal maturation and neovascularization.
Quick-Med's scientists will also present three additional abstracts at the prestigious meeting:
- Antimicrobial Barrier Wound Dressing Optimized for Prophylactic Use: Further development on the commercialized dressing BIOGUARD™ demonstrates why the dressing can be applied prophylactically in situations where other antimicrobial dressings might be unsuitable.
- Stay-Fresh™ Medical Textiles to Interrupt Pathogen Transfer in Healthcare Settings: The novel Stay-Fresh technology has been successfully applied to various textile surfaces, with extremely high efficacy retained after 50 launderings.
- Antimicrobial Dressings: How does Antimicrobial Efficacy Get Tested?: To unwind the conflicting data many companies present, Quick-Med's microbiologists provide an educational guide to the methods to help caregivers better understand the available scientific data.
About NIMBUS
NIMBUS is unique in that it is the only non-leaching antimicrobial dressing; all other antimicrobial dressings rely on the release of chemicals to the wound bed that can impede the wound healing process. NIMBUS forms a sterile bacterial barrier that prohibits the transfer of microorganisms into the wound because the microbicidal agent is irreversibly bound to the dressing. NIMBUS is non-toxic, long-lasting and not blocked by organics such as blood, exudates, urine and perspiration. By design, NIMBUS poses no risk of bacteria developing resistance. Quick-Med's novel NIMBUS antimicrobial technology has been incorporated in BIOGUARD dressings by Derma Sciences, Inc. (OTCBB:DSCI).
"Traditional wound dressings absorb fluid from the wound and act as a great incubator for bacteria that are shed back into the wound," said Gregory Schultz, Professor, Institute for Wound Research at the University of Florida and past President of the Wound Healing Society. "This [NIMBUS] is the first bound, antimicrobial material -- rather than delivering an antimicrobial into the wound, it creates a barrier that won't allow bacteria to penetrate the dressing or grow in the wound fluid."
About the Symposium on Advances Wound Care/Wound Healing Society
Now in its 23rd year, the Symposium is the premier educational wound care program within this clinical field and is one of the largest annual gatherings of wound care clinicians in the United States.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the healthcare and consumer markets. Quick-Med is developing NIMBUS applications in several other advanced wound dressing formats including adhesives, foams, hydrogels, films, and hydrocolloids. For more information, see: www.quickmedtech.com.
© 2009 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® is a registered trademark and Stay Fresh™ is a trademark of Quick-Med Technologies, Inc. BIOGUARD™ is a trademark of Derma Sciences, Inc.
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.